HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test

Executive Summary

After federal agencies invested almost $500m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. It's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.

You may also be interested in...



OTC COVID-19 Tests Have Abbott Seeing Continuing Demand For At-Home Diagnostics

“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.

US FDA Recommendations On Developing Serial COVID-19 Tests Could Accelerate OTC Approval

FDA published a supplemental template for molecular and antigen COVID-19 EUA sponsors with products to be used for serial testing, and a fact sheet that screening program organizers can use to pick the right test.

US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm

Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel